Skip to main content
Premium Trial:

Request an Annual Quote

Athersys Expands Bristol-Myers Squibb Deal

NEW YORK, Aug. 5-Athersys said today that it is expanding its partnership with Bristol-Myers Squibb to provide additional validated drug targets for the next three years.


Under a partnership that began in January 2001, Athersys agreedto use its proprietary human cell line technology to provide the pharmaceutical company with six validated drug targets. In exchange, Athersys receives licensing fees, milestone payments on potential drugs, and royalties on products.


At the time, the partners anticipated expanding the agreement to include up to 50 drug targets.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.